Transformed lymphoma occurs when an indolent lymphoma turns into a more aggressive one. A transformation occurs when genetic changes in the indolent lymphoma cells cause
Read More >
There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma. Unlike traditional chemotherapy that is administered intravenously (IV)
Read More >
Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
Read More >
Hepatitis B is a liver infection caused by the hepatitis B virus (HBV). In some cases, hepatitis can be chronic, therefore lingering in your body
Read More >
On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for a vaccine for the prevention of
Read More >
When Chris Gorelik received news that his central nervous system lymphoma would leave him with months to live, he sought a second opinion and took a chance on a new treatment protocol — to give him a fighting chance to see his children grow up.
Read More >
Emily Tonorezos, MD, MPH, Director of the Office of Cancer Survivorship at the National Cancer Institute (NCI), in the Division of Cancer Control & Population Sciences, shares what she and the agency are doing to raise awareness of and address issues that cancer survivors may face, as well as future directions in cancer survivorship research.
Read More >
With telemedicine trending to be a mainstay in how healthcare professionals treat patients, Ameet Doshi, MD, MBA, Lead Hospitalist for Telemedicine at HealthPartners, shares what is contributing to the surge and how it affects lymphoma patients and survivors.
Read More >Lisocabtagene maraleucel (BREYANZI) is the fourth chimeric antigen receptor (CAR) T cell therapy approved for certain types of non-Hodgkin lymphoma (NHL).
Read More >Umbralisib (UKONIQ, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, has been approved for relapsed or refractory marginal zone lymphoma and follicular lymphoma.
Read More >
